Exacerbations are serious events during the course of the disease and lead to a deterioration in the quality of life. It has been shown that a larger number of exacerbations (more than 2.9 per year) leads to a faster decrease in FEV1 per year.
The cost of treating exacerbations accounts for almost 50% of the total cost.